78
Views
4
CrossRef citations to date
0
Altmetric
Case Report

Giant Fungated Locally Advanced Breast Carcinoma Responded to Hypofractionated Radiotherapy Combined with Apatinib: A Case Report and Literature Review

, , , , , ORCID Icon & show all
Pages 605-611 | Published online: 22 Jan 2021

Figures & data

Figure 1 The pathological results of the rebiopsy pathology of the right breast tumor performed in our hospital. (A) Hematoxylin–eosin-stained sections revealed that the tumor cells grew in a solid and patchy infiltrating manner (original magnification: 200×). (BD) ER, PR, and HER-2 were negative for neoplastic cells by immunohistochemical analysis (original magnification: 200×). (E) CK5/6 was strongly expressed by tumor cells (original magnification: 200×). (F) Ki-67 was expressed in the nuclei of approximately 50% of tumor cells (original magnification: 200×).

Figure 1 The pathological results of the rebiopsy pathology of the right breast tumor performed in our hospital. (A) Hematoxylin–eosin-stained sections revealed that the tumor cells grew in a solid and patchy infiltrating manner (original magnification: 200×). (B–D) ER, PR, and HER-2 were negative for neoplastic cells by immunohistochemical analysis (original magnification: 200×). (E) CK5/6 was strongly expressed by tumor cells (original magnification: 200×). (F) Ki-67 was expressed in the nuclei of approximately 50% of tumor cells (original magnification: 200×).

Figure 2 The effect evaluation between pre-RT and 2 months after RT. (A) The fungated, cauliflower-like tumor occupied the entire right breast before RT. (B) The tumor shrank significantly and eventually fell off 2 months after RT.

Figure 2 The effect evaluation between pre-RT and 2 months after RT. (A) The fungated, cauliflower-like tumor occupied the entire right breast before RT. (B) The tumor shrank significantly and eventually fell off 2 months after RT.

Figure 3 The role of the VEGFR2 inhibitor in the reversal of radioresistance. Apatinib, which acts on the intracellular segment of VEGFR2, inhibited downstream signal activation despite the binding between VEGF with VEGFR2 in vascular endothelial cells, preventing the activation of the following pathways: the Ras/Raf/MEK/ERK pathway, which promotes EC proliferation; and the PI3K/AKT pathway, which inhibits EC apoptosis and promotes EC survival. The activation of VEGF/VEGFR2 could increase the intracellular calcium concentration, activating endothelial nitric oxide synthase, and promoting the production of nitric oxide and prostacyclin. Thus, vascular cell permeability greatly increased, followed by an increase in the interstitial fluid pressure, which is further aggravated by hypoxia. The VEGFR2 inhibitor overcame radiation resistance by inhibiting the proliferation and survival of ECs and reducing hypoxia.

Abbreviations: BAD, Bcl-2 associated death promoter; COX-1/2, cyclooxygenases; DAG, sn-1,2-diacylglycerol; EC, endothelial cell; ERK ½, extracellular regulated kinases 1 and 2; Gab1, Grb2-associated binder-1; IP3, inositol (1,4,5)-trisphosphate; eNOS, endothelial nitric oxide synthase; NO, nitric oxide; PDK1/2, phosphoinositide-dependent kinases 1 and 2; PGI2, prostacyclin; PI3K, phosphoinositide 3-kinase; PIP2, phosphatidylinositol (4,5)-bisphosphate; PIP3, phosphatidylinositol (3,4,5)-trisphosphate; PKB, protein kinase B; PKC, protein kinase C; cPLA2, cytosolic phospholipase A2; PLC-γ, phospholipase C-γ; Shb, Src Homology 2 domain-containing adapter protein B.
Figure 3 The role of the VEGFR2 inhibitor in the reversal of radioresistance. Apatinib, which acts on the intracellular segment of VEGFR2, inhibited downstream signal activation despite the binding between VEGF with VEGFR2 in vascular endothelial cells, preventing the activation of the following pathways: the Ras/Raf/MEK/ERK pathway, which promotes EC proliferation; and the PI3K/AKT pathway, which inhibits EC apoptosis and promotes EC survival. The activation of VEGF/VEGFR2 could increase the intracellular calcium concentration, activating endothelial nitric oxide synthase, and promoting the production of nitric oxide and prostacyclin. Thus, vascular cell permeability greatly increased, followed by an increase in the interstitial fluid pressure, which is further aggravated by hypoxia. The VEGFR2 inhibitor overcame radiation resistance by inhibiting the proliferation and survival of ECs and reducing hypoxia.